Project Grant R44CA310364
Award Date 9/17/25
Completion Date 8/31/27
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- This federal Project Grant award of $714,110.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research by New York University School of Medicine to translate insights in follicular lymphoma for improved diagnosis and classification. The research aims to identify reliable predictive biomarkers to guide frontline risk stratification and treatment for high-risk follicular lymphoma patients, who face a poor prognosis due to early disease...
- This Project Grant award of $306,798 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an artificial intelligence-based system to accurately identify malignant lymph nodes. The key objectives are to: Create a lymph node segmentation model to enable extraction of radiomic features critical for malignancy classification. Develop both cloud-based and standalone desktop deployment options for the classification model to...
- The federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,022,841.00 to Data Driven Bioscience Inc. to validate the DuoSeq platform, a comprehensive genomic profiling assay for the diagnosis of lymphomas. DuoSeq integrates DNA sequencing and RNA sequencing from a single workflow to deliver critical molecular diagnostic readouts, including genetic variants, copy number alterations, translocations, gene expression, and...
- The National Cancer Institute (NCI) awarded a $902,046 Project Grant under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program to Data Driven Bioscience Inc. on January 1, 2025. The grant supports the clinical validation of DuoSeq, a next-generation sequencing (NGS) platform that provides simultaneous DNA and RNA sequencing for the diagnosis of blood cancers. DuoSeq aims to overcome key limitations of existing NGS approaches by streamlining sample preparation,...
- The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $1,274,742 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Northwestern University. The project aims to engineer a high-performing microfluidic system for the rapid, non-invasive isolation and expansion of circulating tumor-reactive lymphocytes (CTRLs) from blood samples. This innovation could accelerate the development of effective anti-tumor cellular...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $677,998 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Medical College of Wisconsin, Inc. (MCW). The project aims to externally validate and integrate radiopathomic models developed using autopsy and biopsy samples to better delineate the true extent of glioma tumors and identify microscopic infiltrating tumor cells. The research will refine...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...